07:00 , Mar 21, 2016 |  BioCentury  |  Product Development

Korea rising

The Korean biopharma industry is mainly known for biosimilars and me-too products. But a cohort of innovator biotechs in Korea is coming of age, bolstered by an infusion of cash from the government and by...
07:00 , Oct 23, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes; obesity G protein-coupled receptor 119 (GPR119) In vitro and mouse studies suggest gordonoside F could help treat obesity and diabetes. In a human...
07:00 , Jun 5, 2014 |  BC Innovations  |  Strategy

Sanford-Burnham goes fourth

Sanford-Burnham Medical Research Institute 's outreach to industry has resulted historically in deals focused either on a narrow range of projects or the work of individual investigators, but the institute also has been seeking broader...
07:00 , Aug 12, 2013 |  BioCentury  |  Emerging Company Profile

Sensor: Combination gut shot

Sensor Pharmaceuticals Inc. is using its Synitivity technology to modify and restrict small molecules to the gut, thereby preventing systemic absorption and reducing potential toxicity. The company expects the improved safety will allow it to...
08:00 , Feb 11, 2013 |  BC Week In Review  |  Company News

Astellas, AstraZeneca deal

Astellas said in its fiscal 3Q earnings for the period ending Dec. 31, 2012, that last November the pharma received notice from AstraZeneca that the pharma decided not to exercise an exclusive 2011 option to...
08:00 , Jan 10, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes G protein-coupled receptor 119 (GPR119) Mouse studies identified a series of indolines that act as selective GPR119 agonists and...
07:00 , Jul 9, 2012 |  BioCentury  |  Strategy

Triple play in diabetes

The addition of Amylin Pharmaceuticals Inc. 's glucagon-like peptide 1 franchise will give partners Bristol-Myers Squibb Co. and AstraZeneca plc three modern mechanisms in their commercial diabetes portfolio and five in the pipeline - more...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Company News

Astellas, AstraZeneca deal

Astellas' Prosidion Ltd. subsidiary granted AstraZeneca an exclusive option to acquire Type II diabetes compounds PSN821 and PSN842, both of which are G protein-coupled receptor 119 (GPR119) agonists. The exercise of the option is contingent...
01:21 , Dec 22, 2011 |  BC Extra  |  Company News

AstraZeneca in deals with Chi-Med, Astellas

Hutchison China MediTech Ltd. (LSE:HCM) jumped 57p (22%) to 320p on Wednesday after partnering with AstraZeneca plc (LSE:AZN; NYSE:AZN) to co-develop and commercialize Chi-Med's volitinib, an inhibitor of c-Met receptor tyrosine kinase that is slated...
07:00 , Oct 13, 2011 |  BC Innovations  |  Strategy

Lilly's opening moves

When Eli Lilly and Co. launched its Phenotypic Drug Discovery Initiative in 2009, its goal was to apply a crowdsourcing approach to finding new small molecules from external investigators that fit the company's core disease...